GnRH agonists and antagonists both suppress the hypothalamic-pituitary-gonadal axis but differ fundamentally in their mechanism and clinical profile.
GnRH agonists cause initial receptor stimulation followed by desensitization and downregulation, while antagonists provide immediate competitive receptor blockade without an initial flare effect.
GnRH agonists (leuprolide, goserelin, triptorelin) bind to pituitary GnRH receptors with high affinity and resist degradation.
This initially stimulates LH and FSH secretion for approximately one week (the “flare-up” effect), followed by receptor desensitization and downregulation over 2 weeks, ultimately producing a hypogonadotropic hypogonadal state.
This pseudo-menopause results from sustained suppression of gonadotropin secretion.
GnRH antagonists (degarelix, cetrorelix, ganirelix, elagolix, relugolix) competitively bind to GnRH receptors, immediately blocking endogenous GnRH action.
They suppress gonadotropin release within hours without any initial stimulatory phase, allowing more rapid suppression and dose-dependent control.
Both classes are used for similar indications but with different profiles:
Prostate cancer: Agonists remain widely used for androgen deprivation therapy, though antagonists (degarelix, relugolix) avoid the testosterone flare and may have lower cardiovascular risk.
Endometriosis: Both reduce estrogen levels and endometrial implants.
Oral antagonists (elagolix, relugolix combination therapy) offer dose-dependent hypoestrogenism with potentially better tolerability and are FDA-approved for endometriosis-associated pain.
Uterine fibroids: Both induce fibroid shrinkage through estrogen suppression.
Assisted reproduction: Antagonists prevent premature LH surge with shorter treatment duration, less gonadotropin use, and substantially lower OHSS risk compared to long agonist protocols, with equivalent live birth rates in most populations.
Antagonist protocols are generally shorter, use fewer total injections, and significantly reduce the risk of Ovarian Hyperstimulation Syndrome (OHSS) compared to traditional long agonist protocols.
Both are used to prevent premature ovulation.
In PCOS patients specifically, antagonists reduce OHSS risk without compromising pregnancy outcomes.
Central precocious puberty: Agonists are standard therapy.
Antagonists offer immediate suppression without flare, shorter treatment courses, lower OHSS risk in IVF, and potentially better cardiovascular safety profiles.
However, agonists have longer clinical experience and established depot formulations.
The choice depends on clinical context, with antagonists increasingly preferred when rapid suppression or OHSS avoidance is prioritized.
Common Medications
Agonists: Leuprolide (Lupron), Goserelin (Zoladex), Triptorelin, and Histrelin.
Antagonists: Degarelix (Firmagon), Relugolix (Orgovyx), Cetrorelix (Cetrotide), and Ganirelix.
Cardiovascular Safety: Meta-analyses suggest that GnRH antagonists may be associated with a lower risk of major adverse cardiovascular events (MACE) compared to agonists, particularly in men with pre-existing heart conditions.